Pharmacokinetics of doxorubicin in pregnant women

Rachel J. Ryu; Sara Eyal; Henry G. Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R. Easterling; Stacey L. Berg; Kathleen A. Scorsone; Eric M. Feldman; Jason G. Umans; Menachem Miodovnik; Mary F. Hebert

doi:10.1007/s00280-014-2406-z

Pharmacokinetics of doxorubicin in pregnant women

Rachel J. Ryu, Sara Eyal, Henry G. Kaplan, Arezoo Akbarzadeh, Karen Hays, Kristin Puhl, Thomas R. Easterling, Stacey L. Berg, Kathleen A. Scorsone, Eric M. Feldman, Jason G. Umans, Menachem Miodovnik, Mary F. Hebert^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Purpose: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. Methods: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. Results: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m²; steady-state volume of distribution (Vss), 1,132 ± 476 L/m²; and terminal half-life (T_1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T _1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m²; Vss, 843 ± 391 L/m²; and T_1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T_1/2 were not significantly different. Conclusions: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.

Original language	English
Pages (from-to)	789-797
Number of pages	9
Journal	Cancer Chemotherapy and Pharmacology
Volume	73
Issue number	4
DOIs	https://doi.org/10.1007/s00280-014-2406-z
State	Published - Apr 2014

Bibliographical note

Funding Information:
Acknowledgments S. eyal, t. r. easterling, S. l. Berg, K. a. Scorsone and M. F. Hebert: grant number U10HD047892 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health and national Center for research resources grant numbers M01rr00037 and rr023256. J.g. Umans and M. Miodovnik: grant number U10HD047891 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health. the content is solely the responsibility of the authors and does not necessarily represent the official views of the eunice Kennedy Shriver national Institute of Child Health & Human Development or the national Institutes of Health.

Keywords

Adriamycin
Doxorubicin
Doxorubicinol
Pharmacokinetics
Pregnancy

Access to Document

10.1007/s00280-014-2406-z

Cite this

@article{3c835af61d7a410f934293edff7b4864,

title = "Pharmacokinetics of doxorubicin in pregnant women",

abstract = "Purpose: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. Methods: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. Results: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m2; steady-state volume of distribution (Vss), 1,132 ± 476 L/m2; and terminal half-life (T1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T 1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m2; Vss, 843 ± 391 L/m2; and T1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different. Conclusions: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.",

keywords = "Adriamycin, Doxorubicin, Doxorubicinol, Pharmacokinetics, Pregnancy",

author = "Ryu, {Rachel J.} and Sara Eyal and Kaplan, {Henry G.} and Arezoo Akbarzadeh and Karen Hays and Kristin Puhl and Easterling, {Thomas R.} and Berg, {Stacey L.} and Scorsone, {Kathleen A.} and Feldman, {Eric M.} and Umans, {Jason G.} and Menachem Miodovnik and Hebert, {Mary F.}",

note = "Funding Information: Acknowledgments S. eyal, t. r. easterling, S. l. Berg, K. a. Scorsone and M. F. Hebert: grant number U10HD047892 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health and national Center for research resources grant numbers M01rr00037 and rr023256. J.g. Umans and M. Miodovnik: grant number U10HD047891 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health. the content is solely the responsibility of the authors and does not necessarily represent the official views of the eunice Kennedy Shriver national Institute of Child Health & Human Development or the national Institutes of Health.",

year = "2014",

month = apr,

doi = "10.1007/s00280-014-2406-z",

language = "אנגלית",

volume = "73",

pages = "789--797",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of doxorubicin in pregnant women

AU - Ryu, Rachel J.

AU - Eyal, Sara

AU - Kaplan, Henry G.

AU - Akbarzadeh, Arezoo

AU - Hays, Karen

AU - Puhl, Kristin

AU - Easterling, Thomas R.

AU - Berg, Stacey L.

AU - Scorsone, Kathleen A.

AU - Feldman, Eric M.

AU - Umans, Jason G.

AU - Miodovnik, Menachem

AU - Hebert, Mary F.

N1 - Funding Information: Acknowledgments S. eyal, t. r. easterling, S. l. Berg, K. a. Scorsone and M. F. Hebert: grant number U10HD047892 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health and national Center for research resources grant numbers M01rr00037 and rr023256. J.g. Umans and M. Miodovnik: grant number U10HD047891 from the eunice Kennedy Shriver national Institute of Child Health & Human Development, national Institutes of Health. the content is solely the responsibility of the authors and does not necessarily represent the official views of the eunice Kennedy Shriver national Institute of Child Health & Human Development or the national Institutes of Health.

PY - 2014/4

Y1 - 2014/4

N2 - Purpose: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. Methods: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. Results: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m2; steady-state volume of distribution (Vss), 1,132 ± 476 L/m2; and terminal half-life (T1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T 1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m2; Vss, 843 ± 391 L/m2; and T1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different. Conclusions: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.

AB - Purpose: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects. Methods: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects. Results: During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m2; steady-state volume of distribution (Vss), 1,132 ± 476 L/m2; and terminal half-life (T1/2), 40.3 ± 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T 1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m2; Vss, 843 ± 391 L/m2; and T1/2, 24.8 ± 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different. Conclusions: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic changes during pregnancy and optimize care for pregnant women.

KW - Adriamycin

KW - Doxorubicin

KW - Doxorubicinol

KW - Pharmacokinetics

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84898058860&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2406-z

DO - 10.1007/s00280-014-2406-z

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 24531558

AN - SCOPUS:84898058860

SN - 0344-5704

VL - 73

SP - 789

EP - 797

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 4

ER -

Pharmacokinetics of doxorubicin in pregnant women

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this